<DOC>
	<DOCNO>NCT02437786</DOCNO>
	<brief_summary>The specific clinical trial part ALK- Abelló directly work explore human immunological mechanism SIT ( observed GRAZAX treatment ) .</brief_summary>
	<brief_title>Molecular Cellular Mechanism Rhinitis Allergic Patients Treated With GRAZAX®</brief_title>
	<detailed_description>The main idea project address study important inflammatory disease ( psoriasis , rheumatoid arthritis , lupus , rhinitis/asthma… ) aim identify novel inflammatory marker .</detailed_description>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<criteria>Written inform consent obtain enter trial . Male female 1865 year age . A clinical history relevant rhinitis rhinoconjunctivitis ( with/without concurrent asthma ) grass pollen least one year prior trial entry . Documented positive specific IgE grass pollen ( IgE ≥ Class 2 ) 5 previous year . Positive Skin Prick Test response ( wheal diameter ≥ 3 mm ) Phleum pratense . Negative pregnancy test childbearing potential female . Willing able comply trial protocol regimen . Previous treatment immunotherapy grass allergen extract . A clinical history symptomatic perennial allergic rhinitis asthma . Patients contraindication immunotherapy establish IT subcommittee EAACI Summary Products Characteristics GRAZAX® . Positive pregnancy test ( fertile female ) . Being immediate family investigator trial staff . A mental condition render subject unable understand nature , scope possible consequence trial , and/or evidence uncooperative attitude . Unlikely able complete trial , reason , likely move , travel extend period time trial period . Use investigational drug within 30 day 5 halflives , whichever long , prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>